Medicure's Q3 2025 Financial Results Reflect Revenue Growth Despite Net Loss

Medicure Inc. reported financial results for the quarter ending September 30, 2025, with revenue rising to $8.2 million, up from $5.2 million in the same period last year. Despite the increase in revenue, the company faced a net loss of $1.4 million, compared to a net income of $680,000 the previous year. The fall in net income is linked to a decrease in AGGRASTAT® revenue and increased costs in the Marley Drug segment.

Revenues from AGGRASTAT® decreased due to pricing pressures from generic alternatives. However, the company's Marley Drug business saw growth, contributing $3.3 million in revenue, partly due to increased sales of ZYPITAMAG®. The newly acquired Gateway and West Olympia Pharmacies also added to the revenue stream.

Medicure's ongoing research and development efforts reflect an investment of $717,000, signifying a focus on innovation. Adjusted EBITDA remained negative at $597,000, influenced by increased selling expenses and cost of goods sold.